498 related articles for article (PubMed ID: 11282007)
1. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.
Bai J; Rossi J; Akkina R
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):385-99. PubMed ID: 11282007
[TBL] [Abstract][Full Text] [Related]
2. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo.
Bai J; Gorantla S; Banda N; Cagnon L; Rossi J; Akkina R
Mol Ther; 2000 Mar; 1(3):244-54. PubMed ID: 10933940
[TBL] [Abstract][Full Text] [Related]
3. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model.
Bai J; Banda N; Lee NS; Rossi J; Akkina R
Mol Ther; 2002 Dec; 6(6):770-82. PubMed ID: 12498773
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts.
Cagnon L; Rossi JJ
Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):251-61. PubMed ID: 10984119
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection.
Anderson J; Akkina R
Retrovirology; 2005 Aug; 2():53. PubMed ID: 16109172
[TBL] [Abstract][Full Text] [Related]
6. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection.
Anderson J; Akkina R
Gene Ther; 2007 Sep; 14(17):1287-97. PubMed ID: 17597795
[TBL] [Abstract][Full Text] [Related]
7. siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS.
Akkina R; Banerjea A; Bai J; Anderson J; Li MJ; Rossi J
Anticancer Res; 2003; 23(3A):1997-2005. PubMed ID: 12894572
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5.
Feng Y; Leavitt M; Tritz R; Duarte E; Kang D; Mamounas M; Gilles P; Wong-Staal F; Kennedy S; Merson J; Yu M; Barber JR
Virology; 2000 Oct; 276(2):271-8. PubMed ID: 11040119
[TBL] [Abstract][Full Text] [Related]
9. Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5.
Cordelier P; Kulkowsky JW; Ko C; Matskevitch AA; McKee HJ; Rossi JJ; Bouhamdan M; Pomerantz RJ; Kari G; Strayer DS
Gene Ther; 2004 Nov; 11(22):1627-37. PubMed ID: 15295615
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human immunodeficiency virus-1 entry using vectors expressing a multimeric hammerhead ribozyme targeting the CCR5 mRNA.
Nazari R; Ma XZ; Joshi S
J Gen Virol; 2008 Sep; 89(Pt 9):2252-2261. PubMed ID: 18753234
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction.
Liang M; Kamata M; Chen KN; Pariente N; An DS; Chen IS
J Gene Med; 2010 Mar; 12(3):255-65. PubMed ID: 20186995
[TBL] [Abstract][Full Text] [Related]
12. Cell-Delivered Entry Inhibitors for HIV-1: CCR5 Downregulation and Blocking Virus/Membrane Fusion in Defending the Host Cell Population.
Symonds G; Bartlett JS; Kiem HP; Tsie M; Breton L
AIDS Patient Care STDS; 2016 Dec; 30(12):545-550. PubMed ID: 27905841
[TBL] [Abstract][Full Text] [Related]
13. CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection.
Zaitseva MB; Lee S; Rabin RL; Tiffany HL; Farber JM; Peden KW; Murphy PM; Golding H
J Immunol; 1998 Sep; 161(6):3103-13. PubMed ID: 9743377
[TBL] [Abstract][Full Text] [Related]
14. Anti-HIV type 1 activity of wild-type and functional defective RANTES intrakine in primary human lymphocytes.
Yang AG; Zhang X; Torti F; Chen SY
Hum Gene Ther; 1998 Sep; 9(14):2005-18. PubMed ID: 9759928
[TBL] [Abstract][Full Text] [Related]
15. Targeting CCR5 with siRNAs: using recombinant SV40-derived vectors to protect macrophages and microglia from R5-tropic HIV.
Cordelier P; Morse B; Strayer DS
Oligonucleotides; 2003; 13(5):281-94. PubMed ID: 15000819
[TBL] [Abstract][Full Text] [Related]
16. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy.
Li MJ; Kim J; Li S; Zaia J; Yee JK; Anderson J; Akkina R; Rossi JJ
Mol Ther; 2005 Nov; 12(5):900-9. PubMed ID: 16115802
[TBL] [Abstract][Full Text] [Related]
17. Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice.
Ringpis GE; Shimizu S; Arokium H; Camba-Colón J; Carroll MV; Cortado R; Xie Y; Kim PY; Sahakyan A; Lowe EL; Narukawa M; Kandarian FN; Burke BP; Symonds GP; An DS; Chen IS; Kamata M
PLoS One; 2012; 7(12):e53492. PubMed ID: 23300932
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of a lentiviral vector containing three anti-HIV genes--CCR5 ribozyme, tat-rev siRNA, and TAR decoy--in SCID-hu mouse-derived T cells.
Anderson J; Li MJ; Palmer B; Remling L; Li S; Yam P; Yee JK; Rossi J; Zaia J; Akkina R
Mol Ther; 2007 Jun; 15(6):1182-8. PubMed ID: 17406343
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.
Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB
Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986
[TBL] [Abstract][Full Text] [Related]
20. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
